Free Trial
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel
OTCMKTS:MCUJF

Medicure Q4 2025 Earnings Results & Report

Medicure logo
$2.76 -0.04 (-1.43%)
As of 10/14/2026 03:58 PM Eastern

Medicure missed analyst earnings expectations but beat on revenue in its Q4 2025 results, released April 23, 2026. The company reported EPS of -$0.29 versus the -$0.0439 consensus estimate, while revenue of $6.13 million topped the $3.62 million estimate by $2.51 million.

Research:ProfileEarnings History

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
After Market Closes

Medicure EPS Results

Actual EPS
-$0.29
Consensus EPS
-$0.0439
Beat/Miss
Missed by -$0.2462
One Year Ago EPS
N/A

Medicure Revenue Results

Actual Revenue
$6.13 million
Expected Revenue
$3.62 million
Beat/Miss
Beat by +$2.51 million
YoY Revenue Growth
N/A

Upcoming Earnings

Medicure's next earnings date is estimated for Thursday, November 19, 2026, based on past reporting schedules.

Conference Call Resources

Medicure Q4 2025 Earnings FAQ

Medicure (OTCMKTS:MCUJF) reported earnings of -$0.29 per share for Q4 2025, missing the consensus estimate of -$0.0439. The report was announced on Thursday, April 23, 2026.

Medicure reported revenue of $6.13 million for Q4 2025, against a consensus estimate of $3.62 million.

Medicure's next earnings date is estimated for Thursday, November 19, 2026. MarketBeat tracks confirmed and estimated earnings dates for Medicure on the company's earnings history page.

Medicure Earnings Headlines

Medicure (OTCMKTS:MCUJF) Stock Crosses Above 50 Day Moving Average - What's Next?
October 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31105044
MEDICURE : ANNOUNCES GRANT OF STOCK OPTIONS
October 1, 2026  |  marketscreener.comM
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.tc pixel
 |  Banyan Hill Publishing (Ad)
Medicure, Inc.: Medicure Announces Completion of Enrollment in Its MEND-PNPO Phase 3 Clinical Trial
September 28, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69697627-medicure-inc-medicure-announces-completion-of-enrollment-in-its-mend-pnpo-phase-3-clinical-trial-200.htm
Medicure Inc (MCUJF) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Acquisitions ...
May 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/medicure-inc-mcujf-q1-2026-210021888.html
Medicure, Inc.: Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call
May 21, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68566676-medicure-inc-medicure-reports-financial-results-for-quarter-ended-march-31-2026-and-schedules-may-25-2026-conference-call-200.htm
See More Medicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Medicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicure and other key companies, straight to your email.

About Medicure

Medicure (OTCMKTS:MCUJF) is a Canadian specialty pharmaceutical company focused on the development and commercialization of cardiovascular medicines. The company is headquartered in Winnipeg, Manitoba, and has concentrated its commercial activities on products intended for use in hospital and acute-care settings.

Medicure’s principal product is AGGRASTAT (tirofiban hydrochloride), an intravenous antiplatelet medication used in the management of certain patients with acute coronary syndrome and other cardiovascular conditions. The product is designed to inhibit platelet aggregation and is marketed primarily through Medicure’s U.S. operations, with the company also pursuing opportunities in other markets where appropriate.

Medicure has historically maintained a focus on cardiovascular drug development, commercialization, and licensing. The company is led by Dr. Albert D. Friesen, who has served as its president and chief executive officer. Medicure’s shares trade in Canada and in the United States under the symbol MCUJF.

View Medicure Profile
Earnings Tools